Tradestie Institutional Equity Comparison Engine

CLYM vs PTN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

CLYM Overall Edge

CLYM Captures Institutional Edge (2โ€“1 Pillars ยท 7โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical while PTN counters with relative strength in Valuation. Fundamentally, CLYM trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus PTN at 42.9x Forward P/E and -65.7% operating margin (-80.1% YoY). In options structure, CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against PTN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner PTN
CLYM N/M vs PTN 42.9x Fwd P/E
Growth & Margin Winner CLYM
Op Margin 0.0% vs -65.7% ยท YoY +0.0% vs -80.1%
Momentum & Technical Winner CLYM
1Y +431.6% vs -43.3% ยท 52W Pos 50% vs 6%
Options & Structure Winner Tie
UNCLASSIFIED (N/A IV) vs UNCLASSIFIED (N/A IV)
CLYM NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.94
-4.05% 1D
Market Cap $608.5M
1M Return +1.22%
1Y Return +431.55%
Forward P/E N/M
Unified AI Score
45.7 / 100 HOLD
Tech 41.0 Fund 47.0 Flow 50.0 Mom 54.0
PTN US Equity
Palatin Technologies, Inc.
Pharmaceutical Preparations
$6.12
-1.69% 1D
Market Cap $11.1M
1M Return +1.74%
1Y Return -43.29%
Forward P/E 42.9x
Unified AI Score
31.5 / 100 SELL
Tech 15.0 Fund 30.0 Flow 50.0 Mom 40.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: CLYM +431.55% PTN -43.29% Spread: +474.84 pp (CLYM Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
CLYM TTM Op. Margin: 0.0% PTN TTM Op. Margin: -65.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs PTN. Trailing 12-month operating profitability (CLYM 0.0% vs PTN -65.7%) and valuation multiples (CLYM N/M vs PTN 42.9x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: CLYM (7) vs PTN (3)
Institutional Metric CLYM PTN Criterion Row Winner
Market Capitalization Scale $608.5M $11.1M Larger Scale CLYM
Trailing P/E Ratio Valuation N/M 42.9x Lower Multiple PTN
Forward P/E Ratio Valuation N/M 42.9x Lower Multiple PTN
Revenue Growth (YoY) Growth +0.0% -80.1% Higher Growth CLYM
Operating Margin (TTM) Profitability 0.0% -65.7% Higher Margin CLYM
Net Profit Margin Profitability 0.0% -63.5% Higher Margin CLYM
Return on Equity (ROE) Capital Efficiency -29.3% -877.5% Higher ROE CLYM
52-Week Range Position Momentum 50% ($2โ€“$18) 6% ($5โ€“$31) Stronger Trend CLYM
Beta / 30D Volatility Risk Regime 1.50ฮฒ ยท 114% Vol 0.87ฮฒ ยท 106% Vol Lower Realized Risk PTN
Unified Institutional Score Composite Signal 45.7 / 100 (HOLD) 31.5 / 100 (SELL) Higher Composite CLYM

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full CLYM vs PTN Buy Guide
CLYM UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live CLYM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
PTN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live PTN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither CLYM nor PTN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.